Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol's Breyanzi, Off To A ‘Good Start,’ Shows Efficacy In Earlier Lymphoma Setting

Executive Summary

The CAR-T therapy met the primary endpoint of improvement in event-free survival in a Phase III trial evaluating Breyanzi as a second-line alternative to stem cell transplant in large B-cell lymphoma.

You may also be interested in...



BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients

Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.

Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah. 

A Vaccines Renaissance , Spurred By COVID-19, Is Underway

The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel